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Abstract
Background: Movement disorders (MD) in children are relatively common and may be associated
with medication use. Objective methods (ie rating scales) and specific research criteria may be
helpful in identifying MD-related adverse events that would otherwise not be apparent from
spontaneous reports. We assessed whether more stringent and rigorous criteria would provide
MD rates similar to those derived subjectively from spontaneous reports.
Methods:  MDs were assessed in children with disruptive behavior disorders (DBDs) and
subaverage intelligence receiving risperidone. Data were from three 1-year, open-label studies in
subjects 4–14 years old. Dyskinesia severity was rated by the Extrapyramidal Symptom Rating Scale
(ESRS) dyskinesia subscale. Tardive dyskinesia (TD) was defined: mild dyskinesia (scores 2, 3) in two
anatomical areas; or moderate dyskinesia (score ≥ 4) in one area for ≥ 4 weeks in subjects without
dyskinesia at baseline (scores 0, 1).
Results: The mean (± SD) age of subjects was 9.4 ± 2.4 years, the mean (± SD) risperidone dose
was 1.6 ± 0.7 mg/day, and the mean (± SD) exposure was 317.8 ± 104.5 days. ESRS data were
available for 668 subjects. Mean ESRS scores were low throughout the study. At baseline, 655
subjects had no dyskinetic symptoms. One subject met predefined TD criteria after a risperidone
dose reduction. Symptoms persisted for 4 weeks, resolving with continued treatment and no
dosage change. Two different subjects had TD by spontaneous adverse-event reports, with
dyskinetic symptoms at 1–2 visits, and symptoms that resolved after treatment discontinuation.
Thirteen subjects had dyskinesia at baseline; their mean ESRS dyskinesia scores decreased at
endpoint.
Conclusion:  Using objective rating scales and research criteria, low-dose risperidone was
associated with low risk of TD and other MDs in children with DBDs in three large 1-year studies.
Careful, objective evaluation of emergent MDs during all stages of treatment is essential for
identifying treatment-emergent TD.
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Background
Disorders that affect movement in children are relatively
common and may be inherited or acquired [1]. Noniatro-
genic movement disorders (MDs) can include dystonia,
dyskinesias, chorea/ballismus, myoclonus, tics, tremor,
stereotypies, and parkinsonism [1,2]. These can be diffi-
cult to distinguish from each other, and some (eg, tics) are
found in association with comorbid conditions such as
attention-deficit/hyperactivity disorder (ADHD), obses-
sive-compulsive disorder (OCD), anxiety disorders, mood
disorders, learning disorders, sleep disorders, conduct and
oppositional behavior, and self-injurious behavior [2].
MDs may also be drug induced; medications that induce
movement disorders include antipsychotics, antiepilep-
tics, beta-adrenergic agonists, amphetamines, and lith-
ium. The identification and classification of MDs
generally, and drug-induced movement disorders specifi-
cally, is quite complex. Although subjective methods (ie
spontaneous adverse events or observations) have tradi-
tionally been used to determine MD rates, objective
research instruments and defined criteria may be more
sensitive than subjective approaches.
Among the best-characterized drug-induced movement
disorders are those associated with antipsychotic treat-
ment [2]. Antipsychotic agents are used in children and
adolescents to treat a range of psychiatric and neurologic
disorders, including schizophrenia, disruptive behavior
disorders (DBDs), Tourette's syndrome, and autism spec-
trum disorders [3-7]. However, while it is acknowledged
that antipsychotics have a definite role in the treatment of
pediatric subjects, there is a dearth of well-controlled effi-
cacy and safety data in this population [3].
Among antipsychotics of any class, the atypical antipsy-
chotic risperidone is the best studied in children and ado-
lescents. Several large, well-controlled studies have
examined the efficacy of risperidone in children with
DBDs and subaverage intelligence (Table 1). Two double-
blind, placebo-controlled, short-term (six-week) studies
noted significant improvements on the primary outcome
measure, the conduct problem subscale of the Nisonger
Child Behavior Rating Form (NCBRF) [8,9]. Long-term
studies of up to two years' duration have indicated that
early improvements in behavioral symptoms are sus-
tained over time and are associated with improvements in
cognitive functioning consistent with age-appropriate
gains [4,10-15]. An eight-week, double-blind, placebo-
controlled study in 101 children with autistic disorder
found that risperidone was significantly superior to pla-
cebo (P < 0.001) in reducing tantrums, aggression, or self-
injurious behavior [16]. Positive responses to risperidone
at eight weeks were maintained at six months in two
thirds of the children [17]. An eight-week, double-blind,
placebo-controlled study in 34 subjects (26 of whom were
children) evaluated the efficacy of risperidone for
Tourette's syndrome. Risperidone significantly reduced tic
severity in comparison with placebo among pediatric sub-
jects [5].
While studies of risperidone have to date suggested treat-
ment benefits, clinical decision making regarding the use
of any antipsychotic agent in younger patients must
include an assessment of the potential risk for movement
disorders. Overall, risperidone treatment in children with
DBDs, autistic disorder, or Tourette's syndrome was
shown to be well tolerated, with low ratings of movement
disorder severity and few movement disorder adverse
events [4,5,8-11,13-16]. Even so, treatment-emergent tar-
dive dyskinesia (TD), because of its persistence and poten-
tial to worsen in severity, remains a particular concern. In
adult subjects, atypical antipsychotics are associated with
a lower risk for TD than are conventional agents and have
been suggested to demonstrate antidyskinetic properties
in subjects with preexisting TD [18]. In a recent meta-anal-
ysis, atypical antipsychotics were associated with a lower
mean annual incidence of TD (0.8%) than was haloperi-
dol (5.4%) [19]. No long-term studies have evaluated
antipsychotic-associated movement disorders in children
and adolescents. Such information is critical in this poten-
tially vulnerable population, particularly when long-term
treatment may be required. Given the rising use of atypical
antipsychotics in pediatric populations across an expand-
ing range of disorders and specialties, it may be beneficial
to apply objective research critiera to determine whether
they are more sensitive in identifying movement disorders
related to atypical antipsychotic use than are spontaneous
reports or observations.
This report is the first to assess TD by defined research cri-
teria [20,21] in a large population of children and adoles-
cent subjects receiving an atypical antipsychotic. Data
were derived from three one-year, open-label, long-term
studies of risperidone in children with DBDs and subaver-
age intelligence [10,11,15].
Methods
Data were from two one-year, open-label extension stud-
ies of short-term, placebo-controlled studies [8,9], and a
one-year, open-label study in children with DBDs and
subaverage intelligence. Detailed descriptions of patient
populations, study designs, treatment, measures, and data
analyses have been published previously [10,11,15]. Insti-
tutional review boards at participating sites approved
individual studies. Written informed consent was pro-
vided by each study participant (if capable) and by the
guardian or legal representative. A responsible party was
required to accompany the participant during study visits,
to provide reliable assessments, and to dispense study
medications.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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Subjects
Participants were recruited from the clinical practices of
the investigators and colleagues; local school districts;
self-referrals via newsletter stories; and newspaper and
radio advertising. Subjects were screened by parent rating
on various instruments (eg, NCBRF [22], Aberrant Behav-
ior Checklist (ABC) [23]), followed by a physical and psy-
chiatric history, and clinician examination. Subjects were
included if they had a DSM-IV diagnosis [20] of conduct
disorder (CD), oppositional defiant disorder, or DBD not
otherwise specified (DBD-NOS) [20,24]; a rating of ≥ 24
on the conduct problem subscales of the NCBRF; a DSM-
IV Axis II diagnosis of mild or moderate mental retarda-
tion [20] or borderline intellectual functioning with an IQ
of ≥ 36 and ≤ 84; and a Vineland Adaptive Behavior Scale
score ≤ 84 [25]. Subjects had to be healthy, and aged
between 4 and 12 years (extension studies) or between 4
and 14 years (separate open-label study). Exclusion crite-
ria included a diagnosis of pervasive developmental disor-
der, schizophrenia, or other psychotic disorder; head
injury as a cause of intellectual disability; a seizure disor-
der requiring medication; females who were sexually
active and without reliable contraception; serious or pro-
gressive illness or clinically abnormal laboratory values; a
history of TD, neuroleptic malignant syndrome, or hyper-
sensitivity to any antipsychotic drug; and known presence
of human immunodeficiency virus. The open-label exten-
sion studies required that participants had completed at
least two weeks of treatment in the preceding double-
blind study and met criteria for continuation in the study.
Subjects were excluded if > 3 weeks had elapsed since their
participation in the previous double-blind trial, or if they
had experienced a hypersensitivity reaction to trial medi-
cation, extrapyramidal symptoms not controlled by med-
ication, an adverse event possibly related to risperidone,
or an adverse event for which they were withdrawn from
the previous trial.
Treatment
Subjects who participated in the open-label extension
studies received a daily risperidone dose of 0.02 to 0.06
mg/kg, with dosing initiated and established in the dou-
ble-blind studies [8,9]. The separate one-year, open-label
study included a three-day screening period and single-
blind treatment with placebo for one week to rule out pla-
cebo responders, followed by entry into the trial by the
remaining subjects. Treatment with risperidone was initi-
ated in the morning or afternoon, beginning with 0.01
Table 1: Short-Term and Long-Term Studies of Risperidone in Pediatric Subjects With Disruptive Behavior Disorders (DBDs)
Citation Population Dosing Duration Results
Aman et al 2002 [8] 118 children aged 5–12 with 
DBDs and subaverage IQ
0.02–0.06 mg/kg/day RIS or 
PBO
6 weeks Significant improvements over 
PBO by week 1 on the NCBRF 
conduct problem subscale; 
significant improvement over 
PBO on all other NCBRF 
subscales
Snyder et al 2002 [9] 110 children aged 5–12 with 
DBDs and subaverage IQ
0.02–0.06 mg/kg/day RIS or 
PBO
6 weeks Significant improvements over 
PBO by week 1 on the NCBRF 
conduct problem subscale; 
significant improvement over 
PBO on all other NCBRF 
subscales
Findling et al 2004 [11] 107 children aged 5–14 with 
DBDs and subaverage IQ 
previously participating in a 6-
week DB study
0.02–0.06 mg/kg/day RIS (mean 
dose, 1.64 mg/day)
1-year OL extension Significant improvements on the 
NCBRF conduct problem 
subscale, most notably during the 
first 4 weeks; significant change 
from baseline on all other 
NCBRF subscales
Turgay et al 2002 [15] 77 children aged 5–12 with 
DBDs and subaverage 
previously participating in a 6-
week DB study
0.02–0.06 mg/kg/day RIS (mean 
dose, 2.38 mg/day)
48-week OL extension Significant improvements on the 
NCBRF conduct problem 
subscale in subjects previously 
receiving PBO in DB study; 
improvements were maintained 
in subjects previously treated 
with risperidone during DB study
Croonenberghs et al 2005 [10] 504 children aged 5–14 years 
with DBDs and subaverage IQ
0.02–0.06 mg/kg/day RIS (mean 
dose, 1.6 ± 0.03 mg/day)
1 year Significant improvement on the 
NCBRF conduct problem 
subscale over baseline as early as 
week 1; improvements were 
maintained over the course of 
the study
Reyes et al 2006 [13] 48 children from [10] aged 7 to 
15 with DBDs, subaverage IQ, 
and comorbid ADHD
0.02–0.06 mg/kg/day (mean 
dose, 1.83 mg/day)
12-month OL extension of 
Findling et al
Significant improvements on the 
NCBRF conduct problem 
subscale were maintained 
through the second year of 
treatment
Reyes et al 2006 [14] 35 children from [10] aged 5–15 
years with DBDs, subaverage 
IQ, and comorbid ADHD
0.02–0.06 mg/kg/day (mean 
dose, 1.92 mg/day)
24-month OL extension of 
Findling et al
Symptoms continued to be well 
controlled, as measured by CGI
IQ indicates intelligence quotient; RIS, risperidone; PBO, placebo; NCBRF, Nisonger Child Behavior Rating Form; DB, double-blind; OL, open-label; ADHD, attention-deficit/
hyperactivity disorder; CGI, Clinical Global Impressions.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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mg/kg for the first two days and changing to 0.02 mg/kg
on day 3. The dosage could be increased weekly thereafter
by 0.02 mg/kg/day to a maximum of 0.06 mg/kg/day.
Allowed concomitant medications included those for pre-
existing medical conditions, psychostimulants (could be
continued for comorbid ADHD for those on a stable dose
for at least 30 days prior to entry), sleep medication (anti-
histamines, chloral hydrate, and melatonin), and anti-
cholinergic medication for any extrapyramidal symptoms
arising during the study.
Measures
Efficacy and safety assessments were completed and have
been detailed elsewhere [8-11,15]. Movement disorders
were assessed using the Extrapyramidal Symptom Rating
Scale (ESRS) [26] at baseline and at weeks 1, 2, 3, 4, 8, 12,
16, 20, 24, 36, 48, and endpoint. Dyskinesia was meas-
ured with the ESRS seven-item dyskinetic movement sub-
scale (subcale items 51–57). These items evaluate lingual,
jaw, buccolabial, truncal, choreoathetoid movements
(upper and lower extremities), and other involuntary
movements. Each item is rated from 0 (absent) to 6
(severe and constant). Raters were trained on the ESRS
using training tapes at a multicenter investigators' meeting
held to standardize procedures. Investigators and/or des-
ignated raters performed ESRS ratings of video-recorded
interviews of patients. Videotapes were available at study
sites to improve the performance of raters and to monitor
inter-rater reliability. Initiation of a study at any site
required evidence of inter-rater ESRS reliability and certi-
fication of raters. Inter-rater reliability required that ≥ 80%
of item ratings of the complete scale should be ± 1 point
of expert ratings, and that ≥ 70% of ratings on individual
items of each ESRS subscale should be ± 1 point of expert
ratings.
In this post hoc analysis, criteria for treatment-emergent
TD were consistent with Schooler and Kane [21] and
DSM-IV [20]. These criteria require that the subject has
dyskinetic movements of at least mild severity in two or
more anatomical areas or of moderate severity in one or
more areas for a duration of ≥ 4 weeks; has onset of symp-
toms beyond week 4 of discontinuing an oral antipsy-
chotic or beyond week 8 of discontinuing a depot
antipsychotic; and has no other conditions that could
cause movement disorders. Since adequate information
on prior antipsychotic use was not available for this pop-
ulation, for the purposes of this analysis, it was assumed
that these patients were neuroleptic naïve. As a conse-
quence of this conservative approach, any dyskinesias in
patients at the beginning of the study were not considered
to be withdrawal dyskinesias.
ESRS criteria for dyskinesia were two or more scores of 2
or 3 (mild), or one score of ≥4 (moderate or greater sever-
ity) on the ESRS dyskinesia subscale. TD was defined as
dyskinesia at two or more consecutive visits (covering four
weeks' duration) in subjects without dyskinetic symptoms
at baseline (all seven ESRS dyskinesia items equal 0 or 1).
ESRS score assignments of mild as a rating of 2 or 3 and
moderate as a rating of 4 on the physician's examination
for dyskinesia subscale were based on a prior analysis
[27].
Data analysis
Movement disorders were evaluated in all patients from
the initiation of risperidone treatment, regardless of study
phase. This represented the beginning of the double-blind
phase in patients who participated in either of the double-
blind studies and who had been randomized to receive
active treatment. This approach enabled the analysis to
include patients who had an onset of dyskinetic symp-
toms during the six-week double-blind exposure period.
For all other patients, movement disorders were evaluated
from the initiation of risperidone treatment at the begin-
ning of the open-label extensions. Data were combined
from the studies. Analyses included all subjects who had
a baseline ESRS assessment and at least two scheduled
post-baseline ESRS assessments. Changes in scores from
baseline to endpoint (last observation carried forward)
were analyzed using two-sided paired T tests or repeated
measure analysis. Mean values and their standard devia-
tion are provided as descriptive statistics.
Results
Baseline and postbaseline ESRS data were available for
668 subjects. The majority of subjects (484, 72.5%) were
from the 1-year, open-label study [10]. The mean age ±
standard deviation (SD) of subjects was 9.4 ± 2.4 years,
and the mean (± SD) IQ was 64.9 ± 13.4. The majority of
subjects were male (81.9%) and most were white
(79.8%). The major AXIS I diagnoses were CD (n = 285,
42.7%), alone (n = 139) or in combination with ADHD
(n = 146); and ODD (n = 280, 41.9%), alone (n = 117) or
in combination with ADHD (n = 163). A total of 268
(40.2%) subjects were diagnosed with borderline intellec-
tual functioning, 273 (40.9%) with mild mental retarda-
tion, and 126 (18.9%) with moderate mental retardation.
Subjects were excluded if they were receiving antipsychot-
ics immediately prior to entry into the open-label study by
Croonenberghs and colleagues or the double-blind, pla-
cebo-controlled studies that preceded the open-label
extensions. The mean (± SD) dose of risperidone in all
studies combined was 1.6 ± 0.7 mg/day, and the mean (±
SD) exposure was 317.8 ± 104.5 days. Twenty-six percent
of patients received stimulant medications during the
trial. A total of 472 (70.7%) of the 668 subjects completed
the respective studies.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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Movement disorders
Mean ESRS scores for the total patient population were
low throughout the study (Table 2). Significant decreases
from baseline to endpoint were noted for the subjective
overall rating (items 1–11; P = 0.0002, df = 667, T = -3.73)
and the physician's examinations for akathisia (item 28; P
< 0.0001, df = 667, T = -5.72). One hundred fifty-two
patients (22.8%) reported a movement disorder-related
adverse event during the study. Among the 50 patients
who discontinued prematurely owing to adverse events,
13 were reported to have a movement disorder-related
adverse event during the study. Seven of 13 patients who
discontinued due to a movement disorder-related adverse
event reported one or more movement disorders at the
time of discontinuation. In five of 13 patients, movement
disorders were the only reported adverse event at discon-
tinuation (case 1, dyksinesia; case 2 dyskinesia and tardive
dyskinesia, case 3, tardive dyskinesia; case 4, extrapyrami-
dal disorder, hypertonia, hypokinesia; case 5, extrapyram-
idal disorder). One patient had dyskinesia at study entry.
Twenty-nine patients (4.3%) received antiparkinsonian
agents during the study. There was no significant differ-
ence in mean dyskinesia scores between patients with or
without stimulant use at baseline or endpoint (baseline, P
= 0.763; endpoint, P = 0.198).
Assessment of emergent tardive dyskinesia
At baseline, 655 subjects (98.1%) were rated as being
without dyskinetic symptoms (all ESRS dyskinesia item
scores 0 or 1). During the study, one (0.2%) patient met
the objective criteria for TD (severity and duration of
symptoms). This patient had a score of 1 on three of the
seven dyskinesia items at baseline. The dyskinetic move-
ments meeting the TD criteria emerged at week 16 after a
second reduction in risperidone dose (at weeks 8 and 12),
suggesting that this was a withdrawal dyskinesia (Table 3).
Symptoms persisted to week 20, for a total duration of
four weeks, and resolved by the next visit with continued
treatment of a stable, reduced dose of risperidone. This
patient did not receive anticholinergic medication and
completed the 48-week study period.
Spontaneous adverse events reports of TD
Two subjects (exclusive of the two subjects described
above) who did not meet the ESRS criteria for TD were
reported to have TD as a spontaneously reported adverse
event. These two subjects were originally reported in the
one-year study by Croonenberghs et al [10]. Table 4 pro-
vides the subjects' characteristics, NCBRF total scores, ris-
peridone doses, and dyskinesia scores. The first patient
was reported to have abnormal movements at week 48
(final study visit). The investigator rated the event as
severe and very likely related to study medication. No
anticholinergic medication was administered, and the
subject received no additional doses of risperidone. The
patient was improved at a follow-up visit 10 days later and
recovered completely in approximately two months. The
second patient reportedly exhibited occasional move-
ments of the lips after 133 days of risperidone treatment.
The investigator rated this event as mild and very likely
related to study medication and reduced the risperidone
dose from 1.6 to 1.0 mg/day. Seven days later, the patient
displayed marked buccal labial movements reported as
moderate TD. Risperidone treatment was discontinued at
that time; he recovered without further treatment in
approximately two weeks.
Effect of treatment on subjects with existing dyskinesia
Thirteen subjects (2.0%) had dyskinetic symptoms at
baseline. The mean age (± SD) of these subjects was 8.5 ±
1.8 years, and 69% were male. The mean IQ (± SD) was
63.4 ± 12.3. Twelve subjects were white, and one was
black. The mean (± SD) risperidone dose was 1.5 ± 0.6
mg/day, and the mean (± SD) exposure was 325.8 ± 104.4
days. Two of the 13 subjects discontinued the study, both
for adverse events. In one patient, the reason for discon-
Table 2: Movement Disorder Ratings in the Total Study Population
ESRS Subscale or Item Possible Range of 
Scores
Mean Baseline Score 
(± SD)
Mean Endpoint 
Score (± SD)
P Value for Change From 
Baseline*
(df, test value)
Subjective overall rating (items 1–11) 0–33 0.80 ± 1.59 0.60 ± 1.39 0.0002
(667, T = -3.73)
Physician's examination for parkinsonism (items 13–30) 0–108 1.07 ± 3.18 0.88 ± 2.35 0.0596
(667, T = -1.89)
Physician's examination for akathisia (item 28) 0–6 0.41 ± 1.07 0.19 ± 0.70 < 0.0001
(667, T = -5.72)
Physician's examination for dyskinesia (items 51–57) 0–42 0.17 ± 1.02 0.12 ± 0.73 0.2155
(617, T = -1.24)
CGI of severity of parkinsonism (item 59) 0–8 0.08 ± 0.46 0.11 ± 0.45 0.2331
(667, T = 1.19)
CGI of severity of dystonia (item 60) 0–8 0.05 ± 0.37 0.04 ± 0.31 0.7534
(667, T = -0.31)
CGI of severity of dyskinesia (item 58) 0–8 0.06 ± 0.39 0.08 ± 0.44 0.3535
(667, T = 0.93)
ESRS indicates Extrapyramidal Symptom Rating Scale; SD, standard deviation; CGI, Clinical Global Impressions.
*Two-sided P value for paired T test.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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tinuation was a movement disorder. There were no obvi-
ous differences between these subjects and the total
population with respect to clinical symptoms, IQ, diagno-
sis, sex, or age. Eleven subjects were from the separate one-
year, open-label study [10], and two were from the study
of Findling and colleagues [11]. Two subjects received
anticholinergics during the study period, and two were
taking stimulants.
Mean ESRS scores at baseline and endpoint are provided
in Table 5. Overall scores were higher for these subjects
with dyskinetic movements than for those not having dys-
kinetic symptoms at baseline. Mean severity of movement
disorder symptoms declined at endpoint for all measures,
significantly so for the physician's examination for parkin-
sonism, akathisia, and dyskinesia, and for the Clinical
Global Impressions (CGI) for parkinsonism and dyski-
nesia (all P < 0.05).
Discussion
Risperidone has been shown to be efficacious in children
with DBDs and subaverage IQ [4,8-11,13-15]. Emerging
evidence suggests that it also may be efficacious in chil-
dren with autism and other neurologic disorders [6,16].
The benefits of antipsychotic treatment in pediatric
patients, however, must be carefully weighed against the
risks. The risk of movement disorders is one such impor-
tant aspect to consider, particularly when choosing
among antipsychotic drugs. This analysis represents the
first assessment of TD by defined research criteria in chil-
dren and adolescents receiving an atypical antipsychotic.
In three long-term trials that included 668 subjects, low-
dose risperidone treatment in pediatric subjects with
DBDs and subaverage IQ was associated with a low risk of
movement disorders, including akathisia. These data are
consistent with a newly published study of low-dose risp-
eridone in pediatric patients [28]. One patient met the
defined research criteria for TD, which emerged after a
dosage reduction. It persisted for four weeks and resolved
with continued treatment and no dosage change. No
patient was identified with persistent TD beyond 4 weeks'
duration.
Notably, there was a disparity between the case of dyski-
nesia, which persisted for 4 weeks and was identified by
defined research criteria for TD, and the two TD cases
identified by spontaneous adverse event reports. These
cases were mutually exclusive. Neither case identified by
adverse event reporting met the research criteria for treat-
ment-emergent TD. This may be due, in part, to the fact
that raters in the trial are trained to use the ESRS, but cli-
nicians were not instructed to use a standardized diagno-
sis of TD for adverse event reporting. Furthermore, the
collection of adverse events via spontaneous reporting by
patients or caregivers may be limited because of a lack of
awareness of dyskinetic movements. A similar finding –
that cases of emergent TD identified by defined research
criteria and those identified by spontaneous event report-
ing are mutually exclusive – was noted in a study of
another database [29]. Nonetheless, the low rate identi-
Table 3: Characteristics in the One Subject With Treatment-Emergent Tardive Dyskinesia as Per Defined Research Criteria
Gender Male
Age 10 y
Diagnosis Oppositional defiant disorder
Intellligence quotient (IQ) 59
NCBRF total score
Baseline 33
Endpoint 31
Time point Risperidone dose (mg/day) Dyskinesia score*
Baseline 0.000 3
Week 1 0.343 3
Week 2 1.200 3
Week 3 1.814 3
Week 4 1.900 3
Week 8 1.784 ---
Week 12 1.300 4
Week 16 1.300 7
Week 20 1.300 7
Week 24 1.300 1
Week 36 1.300 2
Week 48 1.300 0
NCBRF indicates Nisonger Child Behavior Rating Form.
*Extrapyramidal Symptom Rating Scale (ESRS) physician's examination for dyskinesia, items E51–57.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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fied via spontaneous reporting is not less sensitive than
the formal research criteria, as both methods revealed
similar rates.
Thirteen subjects had dyskinetic symptoms at baseline.
The mean severity of dyskinesia symptoms in these sub-
jects decreased significantly when they were treated with
risperidone. The physician's examination of ESRS showed
an overall reduction of reversible movement disorders
during the study, particularly parkinsonism and akathisia,
as well as dyskinetic movements. Of note, these 13
patients also had higher mean ESRS scores for parkinson-
ism. It may be difficult to distinguish between drug-
induced and spontaneous movement disorders (parkin-
sonism, akathisia, etc) and some symptoms of illness,
such as repetitive behaviors and hyperkinesias. It is also
unclear whether patients with cognitive impairment are
more susceptible to neurologic side effects. This difficulty
may have been a factor in certain cases, despite training in
research practices related to movement disorders. A more
systematic evaluation of prior antipsychotic use and
assessment of spontaneous dyskinetic movement would
provide a better understanding of these 13 subjects. The
presence of dyskinetic symptoms in children and adoles-
cents with neurodevelopmental or psychotic disorders
before initiation of risperidone treatment was also noted
Table 5: Extrapyramidal Symptom Rating Scale Scores in the 13 Subjects With Dyskinesia at Baseline
ESRS Subscale or Item Possible Range of 
Scores
Mean Baseline 
Score (± SD)
Mean Endpoint 
Score (± SD)
P Value for Change From Baseline*
(df, test value)
Subjective overall rating (items 1–11) 0–33 4.38 ± 3.28 3.00 ± 4.02 0.2277
(12, T = -1.27)
Physician's examination for parkinsonism (items 13–30) 0–108 9.85 ± 8.21 3.23 ± 3.19 0.0161
(12, T = -2.80)
Physician's examination for akathisia (item 28) 0–6 2.00 ± 1.58 0.69 ± 0.95 0.0083
(12, T = -3.16)
Physician's examination for dyskinesia (items 51–57) 0–42 5.46 ± 3.60 2.23 ± 3.17 0.0166
(12, T = -2.78)
CGI of severity of parkinsonism (item 59) 0–8 1.08 ± 1.44 0.15 ± 0.38 0.0395
(12, T = -2.31)
CGI of severity of dystonia (item 60) 0–8 0.92 ± 1.50 0.08 ± 0.28 0.0591
(12, T = -2.09)
CGI of severity of dyskinesia (item 58) 0–8 2.00 ± 1.22 0.85 ± 1.41 0.0119
(12,T = -2.96)
ESRS indicates Extrapyramidal Symptom Rating Scale; SD, standard deviation; CGI, Clinical Global Impressions.
*Two-sided P value for paired T test.
Table 4: Patient Characteristics in the Two Subjects With Tardive Dyskinesia Reported as an Adverse Event
Case 1 Case 2
Gender Female Male
Age 9 y 7 y
Diagnosis Attention-deficit/hyperactivity disorder – oppositional 
defiant disorder
Disruptive behavior disorder
Intelligence quotient (IQ) 40 52
NCBRF total score
Baseline 47 42
Endpoint 11 31
Timepoint Risperidone dose (mg/day) Dyskinesia score Risperidone dose (mg/day) Dyskinesia score
Baseline 0.300 0 0.300 0
W e e k  1 0 . 6 6 700 . 7 7 80
W e e k  2 0 . 9 1 401 . 0 0 00
W e e k  3 1 . 1 1 401 . 0 0 01
W e e k  4 1 . 2 0 001 . 0 0 00
W e e k  8 1 . 0 9 001 . 5 4 00
Week 12 1.000 0 1.600 0
Week 16 1.000 3 1.580 0
Week 20 1.000 2 0.300 0
Week 24 0.813 1
Week 36 0.800 1
Week 48 0.783 9
NCBRF indicates Nisonger Child Behavior Rating Form.Child and Adolescent Psychiatry and Mental Health 2007, 1:3 http://www.capmh.com/content/1/1/3
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in a retrospective chart review reported by Demb and
Nguyen. Seven of 36 children had positive ratings on one
or more items of the Dyskinesia Identification System:
Condensed User Scale before treatment was initiated [30].
Further, a study that investigated abnormal involuntary
movements in 390 antipsychotic-naive children and ado-
lescents in foster care found that 4.1% of subjects had at
least 2 ratings of 2 (mild) or 1 rating of 3 (moderate) on
any of the first 7 items on the AIMS. The prevalence of
movement disorders by these criteria was significantly
higher in subjects with lower intelligence (IQ ≤69; 10.6%)
compared with those who were more intellectually com-
petent (IQ ≥70; 2.1%) [31]. It appears that lower intelli-
gence itself may confer a risk for movement disorders, and
may help explain the presence of dyskinesia at baseline in
the 13 subjects.
Limitations
Limitations of this report include the open-label, non-
comparative study design, which precluded comparisons
with other antipsychotic agents, either conventional or
atypical. Since these studies were not designed to measure
emergent TD, limited historical data were available
regarding prior medication use that could impact patients'
susceptibility to drug-induced movement disorders.
Although these studies were not designed to assess TD, the
large patient numbers, the frequency of the ESRS evalua-
tions, and the long duration of these studies provided an
opportunity to better understand this pressing clinical
concern. An additional strength of this report was the use
of the ESRS, a comprehensive scale for the assessment of
movement disorders that provides specificity in the detec-
tion of dyskinesias separate from other movement disor-
ders, such as dystonias.
Infrequent visits for the assessment of TD limited the abil-
ity to assess the persistence of dyskinesia in patients with
an onset of symptoms after week 24. Further, TD that
would have emerged beyond the study period described
here would also be undetected. Two subsets of patients
from the study by Croonenberghs et al [10] were followed
for an additional one year (n = 48) (21) or two years (n =
35) of risperidone treatment [13]. Although subjects were
not evaluated for treatment-emergent TD using the
defined criteria applied in this analysis, EPS were rarely
reported as an adverse events. There were no reports of TD
[13,28].
Conclusion
It is essential to carefully assess movement disorders and
TD, and to distinguish those that are treatment-emergent
from those that may be behavioral characteristics of some
pediatric disorders. This analysis of three large, long-term
trials highlights the need for careful, objective evaluation
of emergent movement disorders during all stages of treat-
ment. These data further suggest that treatment with low-
dose risperidone in pediatric subjects with DBDs is associ-
ated with a low rate of TD and other movement disorders.
This safety information, coupled with efficacy results in
other psychiatric and neurologic disorders, is essential for
clinical decision making in young patients, particularly
when long-term use of antipsychotics is anticipated. Addi-
tional large, rigorous studies examining the benefits and
risks of antipsychotics in children and adolescents are
needed.
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